BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 29346247)

  • 1. Concurrent Versus Sequential Intrapleural Instillation of Tissue Plasminogen Activator and Deoxyribonuclease for Pleural Infection.
    Kheir F; Cheng G; Rivera E; Folch A; Folch E; Fernandez-Bussy S; Keyes C; Parikh M; Channick C; Chee A; Majid A
    J Bronchology Interv Pulmonol; 2018 Apr; 25(2):125-131. PubMed ID: 29346247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Cohort Study Evaluating the Safety and Efficacy of Sequential versus Concurrent Intrapleural Instillation of Tissue Plasminogen Activator and DNase for Pleural Infection.
    Goh KJ; Chew WM; Ong JCL; Leong CK; Mohamed Noor IB; Anantham D; Hui LYS; Choong MCM; Liew CJY; Gutierrez MT; Wong JJY; Phua IGCS; Lim WT; Tan QL
    Pulm Med; 2023; 2023():6340851. PubMed ID: 38146504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapleural tissue plasminogen activator and deoxyribonuclease administered concurrently and once daily for complex parapneumonic pleural effusion and empyema.
    Smith D; Shaw H; Ryder T
    Intern Med J; 2023 Dec; 53(12):2313-2318. PubMed ID: 37029951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen Degradation by Neutrophil Elastase in Pleural Infection, Not High Plasminogen Activator Inhibitor-1 (PAI-1), is the Cause of Intrapleural Lytic Failure.
    Barrett CD; Moore PK; Moore EE; Moore HB; Chandler JG; Siddiqui H; Maginot ER; Sauaia A; Pérez-Calatayud AA; Buesing K; Wang J; Davila-Chapa C; Hershberger D; Douglas I; Pieracci FM; Yaffe MB
    Chest; 2024 May; ():. PubMed ID: 38710463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Concurrent Dosing on the Efficacy of Tissue Plasminogen Activator and Deoxyribonuclease in the Treatment of Pleural Infection.
    Pathak V; Adhikari L; Zhou C
    Cureus; 2023 Oct; 15(10):e46683. PubMed ID: 37942362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bronchopleural communication following intrapleural doses of tPA/DNase for empyema.
    Roy B; Teh MC; Kuok YJ; Lee YCG
    Respirol Case Rep; 2020 Oct; 8(7):e00646. PubMed ID: 32884812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Pleural Space Infections in Patients With Indwelling Pleural Catheters for Active Malignancies.
    Chang CH; Ost DE; Jimenez CA; Saltijeral SN; Eapen GA; Casal RF; Sabath BF; Lin J; Cerrillos E; Nevarez Tinoco T; Grosu HB
    J Bronchology Interv Pulmonol; 2024 Apr; 31(2):155-159. PubMed ID: 37982602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between intrapleural urokinase monotherapy and treatment failure in patients with pleural infection: a retrospective cohort study.
    Taniguchi J; Matsui H; Nagai T; Otsuki A; Ito H; Sugimura H; Nakashima K
    BMC Pulm Med; 2023 Jul; 23(1):273. PubMed ID: 37479981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Use of Intrapleural Tissue Plasminogen Activator and Dornase Alfa in Loculated Pleural Effusion Due to Mycobacterium Tuberculosis.
    Ajibola OA; Happel KI
    Cureus; 2023 Nov; 15(11):e49125. PubMed ID: 38125208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapleural alteplase and DNase for complex tuberculous pleurisy: a medical approach.
    Cheong XK; Abdul Hamid MF
    Respirol Case Rep; 2021 Feb; 9(2):e00706. PubMed ID: 33425359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-course intrapleural alteplase and DNase in complex effusion with bleeding risk.
    Cheong XK; Yu-Lin Ban A; Abdul Hamid MF
    Respirol Case Rep; 2020 Oct; 8(7):e00648. PubMed ID: 32864139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Rabbit Model of Retained Hemothorax with Pleural Organization.
    De Vera CJ; Emerine RL; Girard RA; Sarva K; Jacob J; Azghani AO; Florence JM; Cook A; Norwood S; Singh KP; Komissarov AA; Florova G; Idell S
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of pleural infection.
    Elsheikh A; Bhatnagar M; Rahman NM
    Breathe (Sheff); 2023 Dec; 19(4):230146. PubMed ID: 38229682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERS/ESTS statement on the management of pleural infection in adults.
    Bedawi EO; Ricciardi S; Hassan M; Gooseman MR; Asciak R; Castro-Añón O; Armbruster K; Bonifazi M; Poole S; Harris EK; Elia S; Krenke R; Mariani A; Maskell NA; Polverino E; Porcel JM; Yarmus L; Belcher EP; Opitz I; Rahman NM
    Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36229045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rethinking the Doses of Tissue Plasminogen Activator and Deoxyribonuclease Administrated Concurrently for Intrapleural Therapy for Complicated Pleural Effusion and Empyema.
    Innabi A; Surana A; Alzghoul B; Meena N
    Cureus; 2018 Feb; 10(2):e2214. PubMed ID: 30755840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.
    Altmann ES; Crossingham I; Wilson S; Davies HR
    Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study.
    Jiang C; Xie M; Cervellione K; Thurm C
    BMC Res Notes; 2020 Aug; 13(1):368. PubMed ID: 32746902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy for Treatment of Pleural Infection. Randomized Controlled Clinical Trial.
    Kheir F; Thakore S; Mehta H; Jantz M; Parikh M; Chee A; Kaphle U; Sisnega C; Fernandez-Bussy S; Majid A
    Ann Am Thorac Soc; 2020 Aug; 17(8):958-964. PubMed ID: 32421353
    [No Abstract]   [Full Text] [Related]  

  • 19. A systematic review of comorbidities and outcomes of adult patients with pleural infection.
    Cargill TN; Hassan M; Corcoran JP; Harriss E; Asciak R; Mercer RM; McCracken DJ; Bedawi EO; Rahman NM
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31391221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial.
    Luengo-Fernandez R; Penz E; Dobson M; Psallidas I; Nunn AJ; Maskell NA; Rahman NM
    Eur Respir J; 2019 Aug; 54(2):. PubMed ID: 31097519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.